CRON
Cronos Group Inc.
CRON has the edge over OSCR overall, supported by lower modeled downside and stronger fundamentals.
OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
CRON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
CRON's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.8x | $0.62 | -82% |
| Forward | 17x | $3.41 | — |
| Fair | 18x | $2.82 | -17% |
| Current | 21x | $3.41 | — |
| Expensive | 40x | $6.32 | +85% |
Historical ranges are pointers, not guarantees.
CRON's PE is in its fair range at 21x. If earnings grow as analysts expect, today's price would be 17x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CRON in the historical PE scenario, which offers more potential upside but is not a forecast.
CRON Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for CRON, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CRON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.20 | +25% |
| Q3 2026 | $0.16 | +45% |
| Q2 2026 | $0.19 | +217% |
| Q1 2026 | $0.00 | -100% |
| Q4 2025 | -$0.02 | -118% |
| Q3 2025 | $0.11 | +$0.24 |
| Q2 2025 | $0.06 | +$0.21 |
| Q1 2025 | $0.14 | +$0.29 |
| Q4 2024 | $0.11 | +$0.30 |
CRON has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CRON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $63.5M | +75% |
| Q2 2026 | $53M | +58% |
| Q1 2026 | $45.2M | +40% |
| Q4 2025 | $44.5M | +47% |
| Q3 2025 | $36.3M | +6.1% |
| Q2 2025 | $33.5M | +21% |
| Q1 2025 | $32.3M | +28% |
| Q4 2024 | $30.3M | +27% |
CRON's revenue has grown year over year for 13 quarters in a row: $63M last quarter, up 75% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +16 points |
| Q2 2026 | 14% | +30 points |
| Q1 2026 | -4% | +8.6 points |
| Q4 2025 | -17% | +21 points |
| Q3 2025 | -1.4% | +97 points |
| Q2 2025 | -16% | +40 points |
| Q1 2025 | -13% | +51 points |
| Q4 2024 | -38% | +53 points |
CRON has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CRON on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CRON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.4M | +176% |
| Q2 2026 | $22.3M | +$23.3M |
| Q1 2026 | $9M | +$26.4M |
| Q4 2025 | $9.7M | +132% |
| Q3 2025 | $8.8M | +71% |
| Q2 2025 | -$1M | -200% |
| Q1 2025 | -$17.4M | -$13.4M |
| Q4 2024 | $4.2M | -73% |
CRON's free cash flow has turned positive again: $65M over the past year, against −$5M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CRON on cash flow, with more consistent year-over-year improvement.
CRON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -4.3M shares |
| 1 year | -3.7% | -14.3M shares |
| 3 years | -2.7% | -10.4M shares |
| 5 years | -1.3% | -4.9M shares |
| Available history | +8.1% | +27.9M shares |
CRON has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $9.4M |
| Q2 2026 | $16.1M |
| Q1 2026 | $16.7M |
| Q4 2025 | $4.3M |
| Q3 2025 | $1.9M |
CRON spent $47M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -27.0x | Net Cash |
| Q2 2026 | -82.1x | Net Cash |
CRON has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CRON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 62.5 | Neutral |
CRON's weekly RSI is 61 (neutral) and its Stochastic is 62 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CRON PE vs Healthcare Sector
| Metric | CRON | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 54 | 29 | 25 pts above |
CRON is trading at 21x earnings, a 18% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CRON on valuation relative to its sector.
CRON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.33 | 2.4% above |
| 20 week MA | $3.17 | 7.6% above |
| 50 week MA | $2.87 | 19% above |
| 100 week MA | $2.50 | 36% above |
| 200 week MA | $2.31 | 48% above |
CRON is in an uptrend: it's above all five of its weekly moving averages, and 48% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CRON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.88 | $7.48 | +8.7% |
| 2021 | $7.48 | $4.26 | -43% |
| 2022 | $4.26 | $2.54 | -40% |
| 2023 | $2.54 | $2.09 | -18% |
| 2024 | $2.09 | $1.98 | -5.3% |
| 2025 | $1.98 | $2.66 | +34% |
| 2026 YTD | $2.66 | $3.41 | +28% |
CRON has finished lower in four of the last six years. It's up 28% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CRON on returns for 2026, with the stronger performance.